Johnson & Johnson Reports Positive Results in Colorectal Cancer Study Using RYBREVANT Combined with Chemotherapy
Johnson & Johnson has revealed encouraging outcomes from the OrigAMI-1 Phase Ib/II study, exhibiting a 49% overall response rate when RYBREVANT (amivantamab-vmjw) is combined with chemotherapy in patients with metastatic colorectal cancer (mCRC). This trial, focusing on patients with RAS/BRAF wild-type mCRC who had not previously undergone anti-epidermal growth factor receptor (EGFR) therapy, brought forth promising results. RYBREVANT, a fully-human bispecific antibody targeting EGFR and MET, has already been granted approval for certain types of non-small cell lung cancer (NSCLC) in the US and Europe. The OrigAMI-1 study aimed to evaluate the safety and efficacy of RYBREVANT in combination with chemotherapy regimens mFOLFOX6 or FOLFIRI. The recruitment of 43 patients showcased a median progression-free survival of 7.5 months and a median duration of response of 7.4 months. Notably, the treatment displayed significant intrahepatic antitumor activity, particularly in patients with liver metastases. Johnson & Johnson is now set to commence pivotal Phase III trials to further scrutinize RYBREVANT-based regimens for the treatment of colorectal cancer.
Key Takeaways
- Johnson & Johnson has reported a 49% overall response rate in a colorectal cancer study using RYBREVANT combined with chemotherapy.
- RYBREVANT, a bispecific antibody targeting EGFR and MET, has shown notable antitumor activity in metastatic colorectal cancer.
- The study concentrated on RAS/BRAF wild-type mCRC patients who were not previously treated with anti-EGFR therapy.
- Results include a median duration of response of 7.4 months and a median progression-free survival of 7.5 months.
- Johnson & Johnson is preparing to launch Phase III trials to assess RYBREVANT as a first- and second-line treatment for colorectal cancer.
Analysis
The positive Phase Ib/II results for RYBREVANT in metastatic colorectal cancer could potentially have a substantial impact on the pharmaceutical industry, especially in the field of oncology. The 49% response rate, when combined with chemotherapy, suggests a potential breakthrough in treating RAS/BRAF wild-type mCRC. In the short term, this development could bolster J&J's stock and enhance investor confidence, while in the long term, successful Phase III trials could reshape colorectal cancer treatment protocols, ultimately benefiting patients and healthcare systems. Competitors within the oncology sphere may encounter heightened pressure to innovate or engage in collaborative efforts.
Did You Know?
- RYBREVANT (amivantamab-vmjw): A fully-human bispecific antibody targeting both EGFR (Epidermal Growth Factor Receptor) and MET (Mesenchymal-Epithelial Transition factor). This dual targeting mechanism positions RYBREVANT as a promising candidate for treating cancers like non-small cell lung cancer (NSCLC) and now metastatic colorectal cancer (mCRC).
- RAS/BRAF Wild-Type mCRC: Refers to metastatic colorectal cancer (mCRC) patients whose tumors have not mutated in the RAS or BRAF genes. These mutations are common in colorectal cancer and can impact the effectiveness of certain treatments, particularly those targeting the EGFR pathway. Patients with wild-type RAS/BRAF are considered a specific subgroup for whom EGFR-targeted therapies like RYBREVANT may be more efficacious.
- mFOLFOX6 and FOLFIRI: These standard chemotherapy regimens are utilized in the treatment of colorectal cancer. mFOLFOX6 combines oxaliplatin, 5-fluorouracil (5-FU), and leucovorin, while FOLFIRI combines irinotecan, 5-FU, and leucovorin. The study evaluated the combined efficacy and safety of RYBREVANT with these chemotherapy regimens in treating metastatic colorectal cancer.